1st-line Panitumumab plus FOLFIRI or FOLFOX for patients with RAS wildtype metastatic colorectal cancer in Germany – Interim results of the non-interventional study VALIDATE 5. November 2020 J. Uhlig, J. Potenberg, D. Semsek, P. Stübs, C. Fichter, A. Köhler, L. Müller, M. Reiser, H.U. Siebenbach, T. Göhler, L. Jacobasch, V. Kächele, B. Timm, K. Potthoff, N. Marschner, 2020 Download Treatment and outcome of a real-world cohort of patients with advanced, non-squamous NSCLC and KRAS mutations with a special focus on KRAS G12C – real-world data from the German observational, prospective, nation-wide CRISP Registry (AIO-TRK-0315) Griesinger F, Eberhardt WEE2, Hoffknecht P, Metzenmacher M, Wehler T, Kokowski K, Alt J, Schütte W, Jänicke M, Fleitz A, Zacharias S, Hipper A, Buller… Weiterlesen Changes in routine care treatment of patients with multiple myeloma in Germany – results from the MYRIAM registry Engelhardt M, Knauf W, Lipke J, Reiser M, Dörfel S, Kortüm M, Schlag R, von der Heyde E, La Rosée P, Pfannes R, Houet L,… Weiterlesen